Crux Biomedical Overview
Founded
2004
Status
Acquired/Merged
Latest Deal Type
M&A
Latest Deal Amount
$39M
Investors
1
Crux Biomedical General Information
Description
Developer of a preventive device for pulmonary embolisms. The company provide Crux VCF System, that stops the blood clots from reaching the lungs. It is useful for patients at risk of pulmonary embolism who can't tolerate blood thinners, method of preventing clots.
Contact Information
Primary Industry
Surgical Devices
Acquirer
Primary Office
- 1455 Adams Drive
- Suite 1170
- Menlo Park, CA 94025
- United States
+1 (650) 000-0000
Crux Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 12-Dec-2012 | $39M | 000.00 | 0000 | Completed | Generating Revenue |
| 6. Later Stage VC (Series D) | 07-Jun-2011 | 0000 | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series C) | 01-Mar-2011 | 000.00 | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series B) | 22-Jan-2009 | 000 | 000.00 | Completed | Generating Revenue | |
| 3. Later Stage VC | 08-Dec-2008 | 00.00 | 000.00 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series B) | 02-Oct-2007 | $2.25M | $6.1M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 18-Sep-2006 | $3.85M | $3.85M | Completed | Product Development |
Crux Biomedical Executive Team (4)
Crux Biomedical Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alloy Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Emergent Medical Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Individual Investor | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Three Arch Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Ready to get started?
Request a free trial